TOP TEN perturbations for Q9H9B4 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9H9B4
Selected probe(set): 218392_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9H9B4 (218392_x_at) across 5610 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.8888416
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):2.727909
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):2.538927
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):2.5010538
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

tumor supernatant activation study 3 / memory T-cell activation study 1

Relative Expression (log2-ratio):-2.384901
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control memory T-cell activation study 1
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):2.3598423
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):2.3471012
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

lung adenocarcinoma study 3 (negative) / normal lung tissue

Relative Expression (log2-ratio):2.2154503
Number of Samples:9 / 3
Experimental lung adenocarcinoma study 3 (negative)
Primary lung adenocarcinoma samples, with bone marrow negative for early disseminated tumor cells (DTCs). The presence of DTCs can predict the subsequent occurrence of overt metastasis and survival in lung cancer.
Control normal lung tissue
Normal lung tissue.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):2.1872015
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.035119
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.